Pilot Clinical Evaluation of the RHEA Vital Sign Vigilance System in Hospital Patients

Vital Sign Monitoring Clinical Trial

Official title:

Pilot Clinical Evaluation of the RHEA Vital Sign Vigilance System in Hospital Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03356184
• Other study ID #: RHEA EL30-2017-006
• Status: Completed
• Phase: N/A
• Start date: May 11, 2018
• Est. completion date: May 15, 2018

Study information

• Verified date: April 2019
• Source: Darma Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study compares both of the investigational device and reference device to the gold standard Patient Monitor of the accuracy of heart rate and respiratory rate monitoring. The primary variables for the analysis of heart rate (HR) and respiratory rate (RR) are each of the overall mean roots mean square difference (RMSD). Results of the investigational device and reference device compared with the patient monitor is evaluated to see if there are equivalent. Motion and bed exit accuracy will be evaluated by comparing with the manual observation.

Description:

Tests (periods 1 and 2), one of the contact-free devices will be used to monitor the HR and RR, while being compared with the Patient Monitor. The RHEA investigational device and reference device will be used to monitor the same subject at different times, as the sensors of the two devices are placed at a similar location of the bed. HR and RR will be recorded for all three devices.

The primary hypotheses for HR, are as follows:

Adults HO: μ = 3.25 vs. HA: μ < 3.25

The primary hypotheses for RR, are as follows:

Adults HO: μ = 2.25 vs. HA: μ < 2.25 where μ represents the population mean HR or RR. If the upper bound of the confidence interval is less than the hypothesized value, the corresponding null hypothesis will be rejected. Comparison of the performance of the two contract-free devices will be performed on the recorded results via statistical analysis. The hypothesis here is that the two devices have equivalent performance. The third test will assess the ability of the RHEA device to accurately detect motion in or exit from the bed, as compared to the manual observation. Motion and no motion accuracy will each be calculated along with their respective two-sided 95% confidence intervals.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 5
• Est. completion date: May 15, 2018
• Est. primary completion date: May 15, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Male or female, 18 years old and above.

2. Provide written informed consent.

3. Weight ranging from 20 to 150 kg inclusive.

4. Are located in a non-ICU hospital setting.

5. Agree to not eat during the testing period.

6. Agree to keep still.

Exclusion Criteria:

1. Are connected to a device which may interfere with the device monitoring in this study.

2. Are receiving any bedside care which may be incompatible with the study procedures.

3. Sleep apnea.

4. Pregnant or breast feeding.

5. A likely need to receive or undergo a procedure during the testing period.

6. Cannot accept a nasal cannula, or have a monitor lead placed on the chest.

7. A significant medical condition in the judgement of the investigator, which may compromise the study testing procedures.

8. Are wearing pacemaker or defibrillator.

Related Conditions & MeSH terms

• Vital Sign Monitoring

Intervention

Device:
• The Rhea Vital Sign Vigilance Device Group
The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
• The Earlysense System Device Group
The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.

Locations

Country	Name	City	State
United States	Virginia Commonwealth University School of Medicine	Richmond	Virginia

Sponsors (2)

Lead Sponsor	Collaborator
Darma Inc.	Virginia Commonwealth University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Root-mean-square Deviation of Heart Rate	Calculate the root-mean-square deviation (RMSD) of the heart rate using 20 pairs of valid and synchronously recorded heart rate of investigational device and patient monitor.	30 days
Primary	Root-mean-square Deviation of Respiratory Rate	Calculate the root-mean-square deviation (RMSD) of the respiratory rate using 20 pairs of valid and synchronously recorded respiratory rate of investigational device and patient monitor.	30 days
Secondary	Heart Rate t Test Comparison result between the Investigational Device and the Reference Device	Record 20 valid heart rate displayed in the reference device and patient monitor at the same time every one minute.; Calculate the t test results for heart rate for the reference device and the investigational device.	30 days
Secondary	Respiratory Rate t Test Comparison result between the Investigational Device and the Reference Device	Record 20 valid respiratory rate displayed in the reference device and patient monitor at the same time every one minute. Calculate the t test results for respiratory rate for the reference device and the investigational device.	30 days
Secondary	Motion Notification Accuracy(%)	Record the time for each instructed movements from manual observation and time for movements notification shown in the investigational device. Calculate the times matched between these two to get the accuracy.	30 days
Secondary	Bed Exit Notification Accuracy(%)	Record the time for each instructed bed exit from manual observation and time for bed exit notification shown in the investigational device. Calculate the times matched between these two to get the accuracy.	30 days